# A Phase 2 Study of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Diet and Exercise

> **NCT06411275** · PHASE2 · COMPLETED · sponsor: **HighTide Biopharma Pty Ltd** · enrollment: 113 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** HTD1801
- **DRUG:** Placebo
- **DRUG:** HTD1801

## Key facts

- **NCT ID:** NCT06411275
- **Lead sponsor:** HighTide Biopharma Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-31
- **Primary completion:** 2023-01-17
- **Final completion:** 2023-01-17
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2024-05-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06411275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06411275, "A Phase 2 Study of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Diet and Exercise". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06411275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*